Афлиберцепт в лечении заболеваний сетчатки. Обзор клинических исследований
https://doi.org/10.21516/2072-0076-2017-10-2-103-111
Аннотация
Об авторах
Т. Д. ОхоцимскаяРоссия
О. В. Зайцева
Россия
Список литературы
1. Ciulla T.A., Amador A.G., Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003; 26 (9): 2653-64.
2. Zechmeister-Koss I., Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br. J. Ophthalmol. 2012; 96 (2): 167-78.
3. Romero-Aroca. Current status in diabetic macular edema treatments. World J Diabetes. 2013; 4 (5): 165-9.
4. Resnikoff S., Pascolini D., Etya’ale D., et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82 (11): 844-51.
5. Congdon N., O’Colmain B., Klaver C.C., et al. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 2004; 122 (4): 477-85.
6. Rogers S., McIntosh R.L., Cheung N., et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117 (2): 313.e1-319.e1.
7. Wong T.Y., Ferreira A., Hughes R., et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am. J. Ophthalmol. 2014; 157: 9-25.
8. VEGF Trap-Eye (aflibercept ophthalmic solution) briefing document. Ophthalmologic Drugs Advisory Committee. June 17, 2011. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2011.
9. Rudge J.S., Holash J., Hylton D., et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl. Acad Sci USA. 2007; 104 (47): 18363-70.
10. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002; 99 (17): 11393-8.
11. Papadopoulos N., Martin J., Ruan Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15 (2): 171-85.
12. Manual for using the EYLEA® LP-003544 for medical purposes of January 20, 2017.
13. Li X., Lee C., Tang Z., et al. VEGF-B: a survival, or an angiogenic factor? Cell AdhMigr. 2009; 3 (4): 322-7.
14. Rakic J.M., Lambert V., Devy L., et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2003; 44 (7): 3186-93.
15. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001; 7 (5): 575-83.
16. Stewart M.W., Rosenfield P.J. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 2008; 92 (5): 667-8.
17. Fauser S., Schwabecker V., Muether P.S. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am. J. Ophthalmol. 2014; 158 (3): 532-6.
18. Muether P.S., Hermann M.M., Dröge K., et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am. J. Ophthalmol. 2013; 156 (5): 989-93.
19. Muether P.S., Dröge K., Fauser S. Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab. Br. J. Ophthalmol. 2014; 98: 179-81.
20. Sarwar S., Bakbak B., Sadiq M.A., et al. Fusion Proteins: Aflibercept (VEGF Trap-Eye). Dev Ophthalmol. 2016; 55: 282-94.
21. Heier J.S., Brown D.M., Chong V., et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119 (12): 2537-48.
22. Schmidt-Erfurth U., Kaiser P.K., Korobelnik J.F., et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six week results of the VIEW studies. Ophthalmology. 2014; 121 (1): 193-201.
23. CATT Research Group. Martin D.F., Maguire M.G., Ying G.S. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2011; 364: 1897-908.
24. Martin D.F., Maguire M.G., Fine S.L., et al. Comparison of Age related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119: 1388-98.
25. Korobelnik J-F., Do D.V., Schmidt-Erfurth U., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014; 121 (11): 2247-54.
26. Brown D.M., Schmidt-Erfurth U., Do D.V., et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015; 122 (10): 2044-52.
27. Heier J.S., Korobelnik J.F., Brown D.M., et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016 Nov.; 123 (11): 2376-85.
28. DRCRnet, Wells J.A., Glassman A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med. 2015; 372 (13): 1193-203.
29. Korobelnik J.F. Optimal Dose and Cost-effectiveness of Ranibizumab Treatment of Diabetic Macular Oedema. European Ophthalmic Review. 2016; 10 (2): 125-31.
30. Wells J.A., Glassman M.S., Avala A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trials. Ophthalmology. 2016; 123 (6): 1351-9.
31. Available at: http://www.peervoice.com/journal-club-decipheringlatest- data-improve-dme-treatment-choice.
32. Jampol L.M., Glassman A.R., Bressler N.M., et al. JAMA Ophthalmol. Published online October 6, 2016.
33. Boyer D., Heier J., Brown DM., et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012; 119 (5 May): 1024-32.
34. Holz F.G., Roider J., Ogura Y., et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br. J. Ophthalmol. 2013; 97 (3): 278-84.
35. Brown D.M., Heier J.S., Clark W.L., et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am. J. Ophthalmol. 2013; 155 (3): 429-37.
36. Korobelnik J.F., Holz F.G., Roider J., et al. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014; 121 (1): 202-8.
37. Heier J.S., Clark W.L., Boyer D.S., et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014; 121 (7): 1414-20.
38. Ogura Y., Roider J., Korobelnik J.F., et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am. J. Ophthalmol. 2014; 158 (5): 1032-8.
39. Campochiaro P.A., Clark W.L., Boyer D.S., et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015; 122 (3 Mar.): 538-44.
40. Clark W.L., Boyer D.S., Heier J.S., et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016; 123 (2 Feb.): 330-6.
41. Ikuno Y., Ohno-Matsui K., Wong T.Y., et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization. The MYRROR Study. Ophthalmology. 2015; 122: 1220-7.
Рецензия
Для цитирования:
Охоцимская Т.Д., Зайцева О.В. Афлиберцепт в лечении заболеваний сетчатки. Обзор клинических исследований. Российский офтальмологический журнал. 2017;10(2):103-111. https://doi.org/10.21516/2072-0076-2017-10-2-103-111
For citation:
Okhotsimskaya T.D., Zaitseva O.V. Aflibercept for the therapy of retinal diseases. A review of clinical studies. Russian Ophthalmological Journal. 2017;10(2):103-111. (In Russ.) https://doi.org/10.21516/2072-0076-2017-10-2-103-111